| Detailed information |
|---|
| CancerLivER ID | 2544 |
| Biomarker | SQLE, KIAA1919, ALDH4A1, NKTR, DICER1, C1QB, CYP2A6, EIF1AY, LPA, AKR1C4, GNMT, HLA-DRB4, IGFBP2, GPR88, MBD4, DEFA1, MADH1, HFR4, KIAA1847, FTHFD, SAA1, ASS, CRP, APOF, DBY, ATF5, RPS4Y, SAA2 |
| Biomarker Name/Symbol (given in Publication) | SQLE, KIAA1919, ALDH4A1, NKTR, DICER1, C1QB, CYP2A6, EIF1AY, LPA, AKR1C4, GNMT, HLA-DRB4, IGFBP2, GPR88, MBD4, DEFA1, MADH1, HFR4, KIAA1847, FTHFD, SAA1, ASS, CRP, APOF, DBY, ATF5, RPS4Y, SAA2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker associated with HCC progression; but not validated on independent dataset |
| Experimental Condition | Early v/s Late HCV Cirrhosis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in late cirrhosis than early cirrhosis (with more than 3 fold) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 15108252 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 22 patients undergoing liver transplantation for end-stage hepatitis C (without interferon treatment within 6 months of transplant) and 9 patients undergoing liver transplantation for alcoholic cirrhosis and 10 control liver samples (HCV-negative); (1) 5 early HCV cirrhosis ; (2) 8 late HCV-cirrhosi |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Early v/s Late HCV Cirrhosis |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |